Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CA183004 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone. This study will also investigate patient benefit, safety and whether or not vinflunine shrinks or slows the growth of the cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
| |
| 2 | No Intervention | best supportive care for 18 week duration |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| vinflunine and best supportive care | Drug | solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration |
|
| Measure | Description | Time Frame |
|---|---|---|
| duration of Overall Survival after Randomization | 30-March-07 |
| Measure | Description | Time Frame |
|---|---|---|
| patient benefit | 30-Mar-07 | |
| safety | 30-Mar-2007 | |
| response rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Calgary | Alberta | Canada | |||
| Local Institution |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29562804 | Derived | Rassy EE, Bakouny Z, Aoun F, Haddad FG, Sleilaty G, Assi T, Kattan J. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. Immunotherapy. 2018 Jun;10(8):657-663. doi: 10.2217/imt-2017-0190. Epub 2018 Mar 22. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| throughout the study |
| time to response | upon occurrence |
| response duration | throughout the study |
| progression free survival | throughout the study |
| Edmonton |
| Alberta |
| Canada |
| Local Institution | Vancouver | British Columbia | Canada |
| Local Institution | Victoria | British Columbia | Canada |
| Local Institution | Brampton | Ontario | Canada |
| Local Institution | Hamilton | Ontario | Canada |
| Local Institution | Kingston | Ontario | Canada |
| Local Institution | London | Ontario | Canada |
| Local Institution | Toronto | Ontario | Canada |
| Local Institution | Montreal | Quebec | Canada |
| ID | Term |
|---|---|
| D002295 | Carcinoma, Transitional Cell |
| D001749 | Urinary Bladder Neoplasms |
| ID | Term |
|---|---|
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C111217 | vinflunine |
Not provided
Not provided
Not provided